Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

NCT02576990 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Mediastinal Large B-cell Lymphoma
Richter Syndrome

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC